Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta

Autores/as

  • Fabian Juliao-Baños Hospital Pablo Tobón Uribe
  • Carlos Fernando Grillo A Universidad Nacional de Colombia
  • Luis Fernando Pineda Ovalle Centro de enfermedades digestivas, GUT médica
  • William Otero Regino. Universidad Nacional de Colombia
  • María Teresa Galiano de Sánchez. Unidad de Gastroenterología SERVIMED S.A.S.
  • Rafael García Duperly. Fundación Santa Fe de Bogotá
  • María Teresa Vallejo O. Universidad Nacional de Colombia
  • Marcela Torres Amaya. Universidad Nacional de Colombia

DOI:

https://doi.org/10.22516/25007440.637

Palabras clave:

Enfermedad de Crohn, comportamiento, extensión, cicatrización mucosa, terapia biológica, Crohn perianal, Crohn postquirúrgico

Resumen

Objetivo: La enfermedad de Crohn es un trastorno inflamatorio idiopático de etiología desconocida con características genéticas, inmunológicas e influencias del medio ambiente. La incidencia y prevalencia de la enfermedad de Crohn ha aumentado en Colombia. El tratamiento de estos pacientes no es fácil y ha evolucionado en los últimos años, por lo tanto, es necesario desarrollar una Guía de práctica clínica en Colombia, orientada al tratamiento de esta compleja enfermedad para unificar criterios.

Materiales y métodos: Esta guía fue desarrollada por un equipo multidisciplinario con apoyo de la Asociación Colombiana de Gastroenterología, el Grupo Cochrane ITS y el Instituto de Investigaciones Clínicas de la Universidad Nacional de Colombia. Se desarrollaron preguntas clínicas relevantes a la entidad y se realizó la búsqueda de guías nacionales e internacionales en bases de datos especializadas. Las guías existentes fueron evaluadas en términos de calidad y aplicabilidad. El Grupo Cochrane realizó la búsqueda sistemática de la literatura. Las tablas de evidencia y recomendaciones fueron realizadas usando la metodología GRADE.

Resultados: Se realizó una Guía de práctica clínica basada en la evidencia, para el tratamiento tanto médico como quirúrgico de la enfermedad de Crohn en población adulta en Colombia. Se diseñaron algoritmos de manejo, teniendo en cuenta la actividad, el comportamiento y la localización de la enfermedad.

Conclusiones: Se estableció que una adecuada evaluación clínica, endoscópica e imagenológica, así como una estratificación de riesgo individual, es importante para el manejo, y se especificaron las indicaciones para el adecuado tratamiento tanto médico como quirúrgico de estos pacientes. 

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Fabian Juliao-Baños, Hospital Pablo Tobón Uribe

Médico Internista, Especialista en Gastroenterología y Endoscopia Digestiva. Coordinador Clínica de Enfermedad Inflamatoria Intestinal Hospital Pablo Tobón Uribe. Investigador principal, líder de la Guía. Medellín.

Carlos Fernando Grillo A, Universidad Nacional de Colombia

Médico Cirujano, Especialista en Obstetricia y Ginecología, Magíster en Epidemiología Clínica, Profesor Departamento de Ginecología y Obstetricia, Instituto de Investigaciones Clínicas, Universidad Nacional de Colombia, Bogotá.

Luis Fernando Pineda Ovalle, Centro de enfermedades digestivas, GUT médica

Médico cirujano, Especialista en Gastroenterología y Endoscopista Gastrointestinal. Centro de enfermedades digestivas, GUT médica. Bogotá

William Otero Regino. , Universidad Nacional de Colombia

Médico cirujano, Especialista en Gastroenterología y Endoscopista Gastrointestinal. Profesor Titular Facultad de Medicina . Bogotá.

María Teresa Galiano de Sánchez. , Unidad de Gastroenterología SERVIMED S.A.S.

Medica cirujana, Especialista en Gastroenterología y Endoscopista Gastrointestinal. Unidad de Gastroenterología SERVIMED S.A.S y Clínica de Marly. Bogotá.

Rafael García Duperly. , Fundación Santa Fe de Bogotá

Médico Cirujano. Cirujano Coloproctólogo Fundación Santa Fe de Bogotá. Bogotá.

María Teresa Vallejo O. , Universidad Nacional de Colombia

Médica Cirujana, Magister en Epidemiología Clínica. Instituto de Investigaciones Clínicas Universidad Nacional de Colombia.

Marcela Torres Amaya. , Universidad Nacional de Colombia

Química Farmaceuta, Magíster en Epidemiología Clínica, Doctorado en Salud Pública, Instituto de Investigaciones Clínicas Universidad Nacional de Colombia.

Referencias bibliográficas

Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-55. https://doi.org/10.1016/S0140-6736(16)31711-1

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-70. https://doi.org/10.1016/S0140-6736(16)32126-2

de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13-27. https://doi.org/10.1038/nrgastro.2015.186

Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today. 1993;14(9):426-30. https://doi.org/10.1016/0167-5699(93)90244-F

Behr MA, Divangahi M, Lalande JD. What’s in a name? The (mis)labelling of Crohn’s as an autoimmune disease. Lancet. 2010;376(9736):202-3. https://doi.org/10.1016/S0140-6736(10)60282-6

Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012;12(8):570-80. https://doi.org/10.1038/nri3261

Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 2015;50(8):942-51. https://doi.org/10.3109/00365521.2015.1014407

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54. https://doi.org/10.1053/j.gastro.2011.10.001

Ng SC, Shi HY, Hamidi N, Underwood F, Tang W, Benchimol E, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0

Kotze PG, Underwood F, Damiao AOMC, Panaccione R, Ng S, Kaplan G. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: a Systematic Review. Clin Gastroenterol Hepatol. 2020;18(2):304-12. https://doi.org/10.1016/j.cgh.2019.06.030

Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. Curr Opin Gastroenterol. 2019;35(4):259-64. https://doi.org/10.1097/MOG.0000000000000534

Yamamoto-Furusho JK, Sarmiento-Aguilar A, Toledo-Mauriño JJ, Bozada-Gutiérrez K, Bosques-Padilla F, Martínez-Vázquez M, et al. Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017). Medicine (Baltimore). 2019;98(27):e16291. https://doi.org/10.1097/MD.0000000000016291

Juliao F, Damas OM, Arrubla M, Calixto O, Camargo J, Cruz L, et al. The prevalence of inflammatory bowel disease in Colombia is increasing: report on the national prevalente of IBD and description of IBD phenotype. Gastroenterology 2019;156(6):S-405. https://doi.org/10.1016/S0016-5085(19)37865-5

Arguello M, Archila P, Sierra F, Otero W. Enfermedad inflamatoria intestinal. Rev Col Gastroenterol. 1991;6(4):237-72.

Juliao Baños F, Ruiz Vélez MH, Flórez Arango JF, Donado Gómez JH, Marín Zuluaga JI, Monsalve Arango C, et al. Fenotipo e historia natural de la enfermedad inflamatoria intestinal en un centro de referencia en Medellín-Colombia. Rev Col Gastroenterol. 2010;25(3):240-51.

Reyes GA, Gil FL, Carvajal GD, Sánchez C, Aponte D, González C, et al. Enfermedad inflamatoria intestinal: características de fenotipo y tratamiento en un hospital universitario de Bogotá, Colombia. Rev Col Gastroenterol 2018;29 (1):11-8. https://doi.org/10.22516/25007440.196

Rojas CA, Sánchez-Londoño S, Rojas NE, Sepúlveda S, García J, Jiménez D, et al. Descripción clínico-epidemiológica de pacientes con enfermedad inflamatoria intestinal en una clínica de cuarto nivel en Cali. Rev Colomb Gastroenterol. 2020;35(2):166-73. https://doi.org/10.22516/25007440.409

Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota from 1970 Through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857-63. https://doi.org/10.1016/j.cgh.2016.10.039

Enfermedades huérfanas [Internet]. Ministerio de Salud y Protección Social de Colombia; 2020. Disponible en: https://bit.ly/364B42h

Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008;14(Suppl 2):S4-5. https://doi.org/10.1002/ibd.20545

Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-64. https://doi.org/10.1093/ecco-jcc/jjy113

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25. https://doi.org/10.1093/ecco-jcc/jjw168

Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019;157(3):647-59. https://doi.org/10.1053/j.gastro.2019.04.016

Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110(6):802-19. https://doi.org/10.1038/ajg.2015.120

Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369. https://doi.org/10.1136/bmj.c3369

Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. https://doi.org/10.1038/ajg.2015.6

Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7(1):8-15. https://doi.org/10.1097/00054725-200102000-00002

Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence-based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982-1018. https://doi.org/10.1016/j.crohns.2013.09.016

Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827-51. https://doi.org/10.1016/j.crohns.2013.06.001

Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556-85. https://doi.org/10.1016/j.crohns.2013.02.020

Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5a-36a. https://doi.org/10.1155/2005/269076

Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777-82. https://doi.org/10.1136/gut.49.6.777

Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996-1006. https://doi.org/10.1053/j.gastro.2013.07.041

Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35(6):625-33. https://doi.org/10.1111/j.1365-2036.2012.05002.x

Sandborn WJ. Crohn’s disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014;147(3):702-5. https://doi.org/10.1053/j.gastro.2014.07.022

Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zeronico M, et al. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016;10(12):1385-94. https://doi.org/10.1093/ecco-jcc/jjw116

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert J, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22. https://doi.org/10.1093/ecco-jcc/jjz180

Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43(3):317-33. https://doi.org/10.1111/apt.13475

Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(6):1042-50. https://doi.org/10.1016/j.cgh.2013.09.006

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelan W, Bryant R, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110(9):1324-38. https://doi.org/10.1038/ajg.2015.233

Colombel JF, D’haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14(2):254-66. https://doi.org/10.1093/ecco-jcc/jjz131

Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537-45. https://doi.org/10.1038/nrgastro.2015.135

Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3(5):419-28. https://doi.org/10.1177/2050640615590302

Khanna R, Jairath V, Feagan BG. The Evolution of Treatment Paradigms in Crohn’s Disease: Beyond Better Drugs. Gastroenterol Clin North Am. 2017;46(3):661-77. https://doi.org/10.1016/j.gtc.2017.05.010

Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, et al. ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019;13(1):127-37. https://doi.org/10.1093/ecco-jcc/jjy140

Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112(2):241-58. https://doi.org/10.1038/ajg.2016.537

Juliao-Baños F. Calidad en el manejo de enfermedad inflamatoria intestinal. Rev Col Gastroenterol. 2011; 26(3):211-20.

Bitton A, Vutcovici M, Lytvyak E, Kachan N, Bressler B, Jones J, et al. Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. Inflamm Bowel Dis. 2019;25(2):403-9. https://doi.org/10.1093/ibd/izy259

Jackson BD, De Cruz P. Quality of Care in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(3):479-89. https://doi.org/10.1093/ibd/izy276

Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-68. https://doi.org/10.1016/j.crohns.2013.12.013

Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S. Infection Risk with Biologic Therapy in Patients with Inflammatory Bowel Disease. Clin Pharmacol Ther. 2017;102(4):633-41. https://doi.org/10.1002/cpt.791

Nguyen NH, Singh S, Sandborn WJ. Positioning Therapies in the Management of Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(6):1268-79. https://doi.org/10.1016/j.cgh.2019.10.035

Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment Algorithms for Crohn’s Disease. Digestion. 2020;101(Suppl 1):43-57. doi: 10.1159/000506364. Epub 2020 Mar 13. PMID: 32172251.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-42. https://doi.org/10.1503/cmaj.090449

Grupo de actualización de la Guía Metodológica para el desarrollo de Guías de Práctica Clínica con Evaluación Económica en el SGSSS Colombiano. Guía Metodológica para la elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano: Ministerio de Salud y Protección Social; 2014. Disponible en: https://bit.ly/2I8nAdu

Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62(10):1013-20. https://doi.org/10.1016/j.jclinepi.2008.10.009

Higgins J, Altman D. Assessing risk of bias in included studies. En: Higgins J, Green S (editores). Cochrane Handbook for Systematic Reviews of Interventions. Londres: The Cochrane Collaboration; 2011.

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026

National Institute for Health and Clinical Excellence. Crohn’s disease: management in adults, children and young people. Disponible en: https://bit.ly/2I6zYe1

Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, et al. Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut. 2008;57(10):1386-92. https://doi.org/10.1136/gut.2007.134817

Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY. A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm Bowel Dis. 2006;12(7):551-7. https://doi.org/10.1097/01.ibd.0000225334.60990.5b

Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22(3):340-5. https://doi.org/10.1097/MEG.0b013e32832bab49

Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-9. https://doi.org/10.1002/ibd.22861

Dulai PS, Peyrin-Biroulet L, Danese S, Sands B, Dignass A, Turner D, et al. Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019;157(4):1032-43. https://doi.org/10.1053/j.gastro.2019.06.018

Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn›s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390(10114):2779-89. https://doi.org/10.1016/S0140-6736(17)32641-7

Moore C, Corbett G, Moss AC. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(5):619-25. https://doi.org/10.1093/ecco-jcc/jjw007

Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, et al. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn›s disease. World J Gastroenterol. 2017;23(23):4285-92. https://doi.org/10.3748/wjg.v23.i23.4285

Choi SH, Kim KW, Lee JY, Kim K, Park S. Diffusion-weighted magnetic resonance enterography for evaluating bowel inflammation in Crohn›s disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2016;22(3):669-79. https://doi.org/10.1097/MIB.0000000000000607

Allocca M, Danese S, Laurent V, Peyrin-Biroulet L. Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020;18(6):1309-23. https://doi.org/10.1016/j.cgh.2019.11.052

Niv Y. Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn›s disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(7):844-8. https://doi.org/10.1097/MEG.0000000000000881

Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn›s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21-35. https://doi.org/10.1097/01.MIB.0000437495.30052.be

Limketkai BN, Akobeng AK, Gordon M, Adepoju AA. Probiotics for induction of remission in Crohn›s disease. Cochrane Database Syst Rev. 2020;7(7):CD006634. https://doi.org/10.1002/14651858.CD006634.pub3

Su JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn›s disease: a systematic review and meta-analysis. J Dig Dis. 2015;16(2):58-66. https://doi.org/10.1111/1751-2980.12216

Townsend CM, Parker CE, MacDonald JK, Nguyen T, Jairath V, Feagan B, et al. Antibiotics for induction and maintenance of remission in Crohn›s disease. Cochrane Database Syst Rev. 2019;2(2):CD012730. https://doi.org/10.1002/14651858.CD012730.pub2

Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn›s disease. Cochrane Database Syst Rev. 2016;10:Cd000545. https://doi.org/10.1002/14651858.CD000545.pub5

Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn›s disease. Cochrane Database Syst Rev. 2016;7:CD008870. https://doi.org/10.1002/14651858.CD008870.pub2

McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn›s disease. Cochrane Database Syst Rev. 2014(8): CD003459. https://doi.org/10.1002/14651858.CD003459.pub4

Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, et al. Budesonide for induction of remission in Crohn›s disease. Cochrane Database Syst Rev. 2015(6): CD000296. https://doi.org/10.1002/14651858.CD000296.pub4

Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn›s disease. Cochrane Database Syst Rev. 2008(2):CD006792. https://doi.org/10.1002/14651858.CD006792.pub2

Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, et al. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn›s Disease: A Bayesian Network Meta-analysis. Inflamm Bowel Dis. 2017;23(3):461-72. https://doi.org/10.1097/MIB.0000000000001023

Qiu Y, Li MY, Feng T, Feng R, Mao R, Chen BL, et al. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn›s disease. Stem Cell Res Ther. 2017;8(1):136. https://doi.org/10.1186/s13287-017-0570-x

Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn›s disease. Cochrane Database Syst Rev. 2016;9:CD003715. https://doi.org/10.1002/14651858.CD003715.pub3

Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn›s disease. Cochrane Database Syst Rev. 2015(10):CD000067. https://doi.org/10.1002/14651858.CD000067.pub3

Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, et al. Budesonide for maintenance of remission in Crohn›s disease. Cochrane Database Syst Rev. 2014(8):CD002913. https://doi.org/10.1002/14651858.CD002913.pub3

Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn›s disease. Cochrane Database Syst Rev. 2014(8):CD006884. https://doi.org/10.1002/14651858.CD006884.pub3

Tsertsvadze A, Gurung T, Court R, Clarke A, Sutcliffe P. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn›s disease: a systematic review and meta-analysis. Health Technol Assess. 2015;19(26):1-138. https://doi.org/10.3310/hta19260

Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn›s disease. Cochrane Database Syst Rev. 2018;4(4):CD000542. https://doi.org/10.1002/14651858.CD000542.pub3

Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(4):389-400. https://doi.org/10.1111/apt.14203

Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn›s disease. Cochrane Database Syst Rev. 2003(4):CD000301. https://doi.org/10.1002/14651858.CD000301

Cottone M, Kohn A, Daperno M, Castiglione F, Annese V, Orlando A. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30-5. https://doi.org/10.1016/j.cgh.2010.09.026

Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc. 2014;89(12):1621-35. https://doi.org/10.1016/j.mayocp.2014.08.019

Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn›s disease. Aliment Pharmacol Ther. 2018;48(4):394-409. https://doi.org/10.1111/apt.14852

Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613-23. https://doi.org/10.1111/apt.13083

de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn›s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016;18(7):667-75. https://doi.org/10.1111/codi.13311

MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn›s disease. Cochrane Database Syst Rev. 2016;11:CD007572. https://doi.org/10.1002/14651858.CD007572.pub3

Davies SC, Nguyen TM, Parker CE, MacDonald JK, Jairath V, Khanna R. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn›s disease. Cochrane Database Syst Rev. 2019;12(12):CD012804. https://doi.org/10.1002/14651858.CD012804.pub2

Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al. Biologic Therapies and Risk of Infection and Malignancy in Patients with Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385-97. https://doi.org/10.1016/j.cgh.2016.04.039

Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative Risk of Serious Infections with Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(1):69-81. https://doi.org/10.1016/j.cgh.2019.02.044

Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043-57. https://doi.org/10.1111/apt.13990

Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn›s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344-54. https://doi.org/10.1053/j.gastro.2014.10.011

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn›s disease. N Engl J Med. 2004;350(9):876-85. https://doi.org/10.1056/NEJMoa030815

McSharry K, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn›s disease. Aliment Pharmacol Ther. 2011;34(11-12):1282-94. https://doi.org/10.1111/j.1365-2036.2011.04873.x

Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn›s disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125(2):380-8. https://doi.org/10.1016/S0016-5085(03)00877-1

Cirocchi R, Santoro A, Trastulli S, Farinella E, Di Rocco G, Vendettuali D, et al. Meta-analysis of fibrin glue versus surgery for treatment of fistula-in-ano. Ann Ital Chir. 2010;81(5):349-56.

Ruffolo C, Scarpa M, Bassi N, Angriman I. A systematic review on advancement flaps for rectovaginal fistula in Crohn’s disease: transrectal vs transvaginal approach. Colorectal Dis. 2010;12(12):1183-91. https://doi.org/10.1111/j.1463-1318.2009.02029.x

Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther. 2015;42(7):783-92. https://doi.org/10.1111/apt.13356

Cao Y, Ding Z, Han C, Shi H, Cui L, Lin R. Efficacy of Mesenchymal Stromal Cells for Fistula Treatment of Crohn’s Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017;62(4):851-60. https://doi.org/10.1007/s10620-017-4453-x

Lightner AL, Wang Z, Zubair AC, Dozois EJ. A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn’s Disease: Progress Made and Future Directions. Dis Colon Rectum. 2018;61(5):629-40. https://doi.org/10.1097/DCR.0000000000001093

Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan B, Lobo A, et al. Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879-92. https://doi.org/10.1016/j.cgh.2018.01.030

El-Hussuna A, Krag A, Olaison G, Bendtsen F, Gluud LL. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn’s disease: a systematic review. Dis Colon Rectum. 2013;56(12):1423-33. https://doi.org/10.1097/DCR.0b013e3182a48505

Qiu Y, Zheng Z, Liu G, Zhao X, He A. Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. United Eur Gastroenterol J. 2019;7(9):1198-214. https://doi.org/10.1177/2050640619878998

Ahmed Ali U, Martin ST, Rao AD, Kiran RP. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn’s disease. Dis Colon Rectum. 2014;57(5):663-74. https://doi.org/10.1097/DCR.0000000000000099

Nguyen DL, Nguyen ET, Bechtold ML. Outcomes of initial medical compared with surgical strategies in the management of intra-abdominal abscesses in patients with Crohn’s disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2015;27(3):235-41. https://doi.org/10.1097/MEG.0000000000000273

Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D, et al. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn’s disease strictures. Aliment Pharmacol Ther. 2015;42(10):1137-48. https://doi.org/10.1111/apt.13388

Reese GE, Purkayastha S, Tilney HS, von Roon A, Yamamoto T, Tekkis PP. Strictureplasty vs resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 2007;9(8):686-94. https://doi.org/10.1111/j.1463-1318.2006.01114.x

Dasari BV, McKay D, Gardiner K. Laparoscopic versus open surgery for small bowel Crohn’s disease. Cochrane Database Syst Rev. 2011(1):CD006956. https://doi.org/10.1002/14651858.CD006956.pub2

He X, Chen Z, Huang J, Lian L, Rouniyar S, Wu X, et al. Stapled side-to-side anastomosis might be better than handsewn end-to-end anastomosis in ileocolic resection for Crohn’s disease: a meta-analysis. Dig Dis Sci. 2014;59(7):1544-51. https://doi.org/10.1007/s10620-014-3039-0

Tekkis PP, Purkayastha S, Lanitis S, Athanasiou T, Heriot AG, Orchard TR, et al. A comparison of segmental vs subtotal/total colectomy for colonic Crohn’s disease: a meta-analysis. Colorectal Dis. 2006;8(2):82-90. https://doi.org/10.1111/j.1463-1318.2005.00903.x

Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009(4):CD006873. https://doi.org/10.1002/14651858.CD006873.pub2

Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2014(8):CD010233. https://doi.org/10.1002/14651858.CD010233.pub2

Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2011(1):CD008414. https://doi.org/10.1002/14651858.CD008414.pub2

Nguyen DL, Solaimani P, Nguyen ET, Jamal MM, Bechtold ML. Anti-tumor necrosis factor alpha is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn’s disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26(10):1152-9. https://doi.org/10.1097/MEG.0000000000000178

Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV, Jr. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1):64-76. https://doi.org/10.1053/j.gastro.2014.09.031

Burr NE, Hall B, Hamlin PJ, Selinger CP, Ford AC, O’Connor A. Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn’s Disease. J Crohns Colitis. 2019;13(6):693-701. https://doi.org/10.1093/ecco-jcc/jjy216

Carla-Moreau A, Paul S, Roblin X, Genin C, Peyrin-Biroulet L. Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Dig Liver Dis. 2015;47(3):191-6. https://doi.org/10.1016/j.dld.2014.11.005

McCombie AM, Mulder RT, Gearry RB. How IBD patients cope with IBD: a systematic review. J Crohns Colitis. 2013;7(2):89-106. https://doi.org/10.1016/j.crohns.2012.05.021

Ha FJ, Thong L, Khalil H. Quality of Life after Intestinal Resection in Patients with Crohn Disease: A Systematic Review. Dig Surg. 2017;34(5):355-63. https://doi.org/10.1159/000453590

Mahadev S, Young JM, Selby W, Solomon MJ. Quality of life in perianal Crohn’s disease: what do patients consider important? Dis Colon Rectum. 2011;54(5):579-85. https://doi.org/10.1007/DCR.0b013e3182099d9e

Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum. 2007;50(5):586-97. https://doi.org/10.1007/s10350-006-0847-0

Publicado

2020-11-30

Cómo citar

Juliao-Baños, F., Grillo A, C. F. ., Pineda Ovalle, L. F., Otero Regino. , W. ., Galiano de Sánchez. , M. T., García Duperly. , R. ., Vallejo O. , M. T. ., & Torres Amaya. , M. . (2020). Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta . Revista Colombiana De Gastroenterología, 35(Supl. 2), 63–200. https://doi.org/10.22516/25007440.637